Xiaoxin Ren

Hebei Agricultural University — China

Immunology and Microbiology · Life Sciences

13h-index577citations33works8.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immune Cell Function and Interaction(10), Cancer Immunotherapy and Biomarkers(8), CAR-T cell therapy research(6), Immunotherapy and Immune Responses(5), HIV Research and Treatment(4)

Publications33 total

418 Novel PD-1xKIR3DL3 bispecific antibodies take the brakes off T and NK cells
Regular and Young Investigator Award Abstracts·2025Open Access
Development of novel and efficient Corynebacterium glutamicum gene expression systems for industrial enzyme production
Journal of Microbiological Methods·2025
Deep learning-based 6-DoF visual relocalization assisted simultaneous localization and mapping (SLAM)
Industrial Robot the international journal of robotics research and application·2025
Development of the Novel and Efficient Corynebacterium Glutamicum Gene Expression Systems for Industrial Enzyme Production
SSRN Electronic Journal·2025Open Access
DDR-YOLO: An Efficient Detection Model Based on YOLO11s for Steel Surface Defect
IEEE Access·2025· 2 citedOpen Access
TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells
Nature Communications·2024· 47 citedOpen Access
A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progression
Developmental Cell·2023· 20 citedOpen Access
Adult T-Cell Leukemia/Lymphoma Diagnosed in North American Is Characterized By a Requirement for BCL6 and a Cell Cycle Program Associated with DNA Replication Stress
Blood·2022
Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell–mediated antitumor immunity
Journal of Clinical Investigation·2022· 52 citedOpen Access
Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model
STAR Protocols·2022· 2 citedOpen Access
489 NPX267, a first-in-class monoclonal antibody targeting KIR3DL3, blocks HHLA2-mediated immunosuppression and potentiates T and NK cell-mediated antitumor immunity
Regular and Young Investigator Award Abstracts·2022· 5 citedOpen Access
Abstract 6395: Butyrophilins 3A as an immune checkpoint and a therapeutic target in hematological malignancies
Cancer Research·2022
Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities
Genes & Diseases·2021· 23 citedOpen Access
Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting
Stem Cell Investigation·2021· 18 citedOpen Access
KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target
Science Immunology·2021· 86 citedOpen Access
Dynamics of Leukocyte Subpopulations Reconstitution Predict Infection Propensity in a Multiethnic Real World Cohort Treated with Anti-CD19 CAR-T Cell Therapy (Axicabtagene-Ciloleucel)
Transplantation and Cellular Therapy·2021· 1 cited
Prognostic Factors for North American Adult T Cell Leukemia Lymphoma: Defining Risk Groups Using a Four-Point Score Prognostic System
Blood·2020
Dynamics of Leukocyte Subpopulations Reconstitution Predict Infection Propensity in a Multiethnic Real World Cohort Treated with Anti-CD19 CAR-T Cell Therapy (Axicabtagene-Ciloleucel)
Blood·2020· 1 cited
Abstract 1017: RICTOR/mTOR signaling regulates novel immune checkpoints in non-small cell lung cancer (NSCLC)
Cancer Research·2020
Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade
Blood·2019· 103 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Xingxing Zang(22), Murali Janakiram(9), R. Alejandro Sica(8), Hao Wang(7), Christopher Nishimura(7), Amit Verma(6), Jian‐Hua Wang(6), Ulrich Steidl(5), Phillip M. Galbo(4), Bijan Etemad-Gilbertson(4), Deyou Zheng(4), Kith Pradhan(4), Chuan Li(4), Li Wu(4), Haibo Wang(4), Astha Thakkar(4), Zhu Cui(4), Amanda Lombardo(4), Fariha Khatun(4), Kailyn Gillick(4)